Alumis (ALMS) vs Ardelyx (ARDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Alumis (ALMS) has outperformed Ardelyx (ARDX) over the past year, gaining 58.1% versus a loss of 35.2%. Alumis is the larger company by market cap ($926.8 million vs $846.9 million), about 1.1 times the size. Ardelyx converts more of its revenue into profit, with a net margin of -15.1% versus -1011.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | ARDX |
|---|---|---|
| Share price | $7.16 | $3.28 |
| Market cap | $926.76M | $846.86M |
| 1-day change | +2.73% | +0.31% |
| YTD return | -26.64% | -43.74% |
| 1-year return | +58.06% | -35.18% |
| 5-year return | — | +203.70% |
| Forward P/E | — | 11.29 |
| EPS (TTM) | $-3.86 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $24.05M | $407.32M |
| Revenue growth (YoY) | — | +22.09% |
| Net income (latest FY) | $-243.32M | $-61.60M |
| Gross margin | — | 90.29% |
| Operating margin | -1886.92% | -10.06% |
| Net margin | -1011.75% | -15.12% |
| 52-week high | $31.35 | $8.40 |
| 52-week low | $4.37 | $3.18 |
| Distance from 52-week high | -77.16% | -60.95% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +348.74% | +293.29% |
| Average volume | 2.45M | 4.17M |
| Shares outstanding | 129.44M | 258.19M |
| Employees | 237 | 489 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALMS has outperformed ARDX by 93.2 percentage points over the past year.
- Ardelyx is more profitable, keeping -15.1 cents of every revenue dollar as net income versus -1011.7 cents for Alumis.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 237 employees
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
ALMS vs ARDX FAQ
Which is bigger, Alumis or Ardelyx?
Alumis (ALMS) is larger, with a market capitalization of $926.76M compared with $846.86M for Ardelyx (ARDX).
Which stock has performed better over the past year, ALMS or ARDX?
ALMS returned +58.06% over the past 12 months, compared with -35.18% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and Ardelyx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.